Pancreatic Adenocarcinoma, Version 1.2019.

The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and management of adenocarcinomas of the exocrine pancreas and are intended to assist with clinical decision-making. These NCCN Guidelines Insights discuss important updates to the 2019 version of the guidelines, focusing on postoperative adjuvant treatment of patients with pancreatic cancers.

[1]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[2]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[3]  Z. Stadler,et al.  An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. , 2020, JAMA oncology.

[4]  H. Cohen,et al.  Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. , 2020, Journal of geriatric oncology.

[5]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[7]  FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC , 2019, Case Medical Research.

[8]  J. Shim,et al.  Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis , 2019, Clinical Rheumatology.

[9]  Joon-Oh Park,et al.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. , 2019, The New England journal of medicine.

[10]  FDA approves larotrectinib for solid tumors with NTRK gene fusions , 2018, Case Medical Research.

[11]  J. Krauss,et al.  Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  Funda Meric-Bernstam,et al.  Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.

[13]  S. Gill,et al.  Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX , 2017, American journal of clinical oncology.

[14]  Jin‐Young Jang,et al.  of the pancreas , 2017 .

[15]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[16]  S. Amar,et al.  Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  P. Philip,et al.  Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial , 2017, JAMA oncology.

[18]  W. Greenhalf,et al.  Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine‐based chemotherapy , 2017, The British journal of surgery.

[19]  H. Ueno,et al.  Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer , 2017, Cancer Chemotherapy and Pharmacology.

[20]  H. Arkenau,et al.  Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now? , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Lee,et al.  A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea , 2017, Medicine.

[22]  W. Bamlet,et al.  Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Reni,et al.  Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer , 2016, British Journal of Cancer.

[24]  S. Gill,et al.  PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Chien,et al.  Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis , 2016, British Medical Journal.

[26]  T. Conroy,et al.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. , 2016, The Lancet. Oncology.

[27]  Yan-Shen Shan,et al.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial , 2016, The Lancet.

[28]  D. Cunningham,et al.  Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. , 2016 .

[29]  R. Salem,et al.  Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.

[30]  M. Reni,et al.  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  R. Korn,et al.  Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  M. Besselink,et al.  [New developments in the treatment of pancreatic cancer]. , 2016, Nederlands tijdschrift voor geneeskunde.

[33]  D. V. Von Hoff,et al.  Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). , 2016, European journal of cancer.

[34]  N. Petrelli,et al.  Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds , 2016, Annals of Surgical Oncology.

[35]  K. Offit,et al.  Identification of germline genetic mutations in patients with pancreatic cancer , 2015, Cancer.

[36]  P. Hartge,et al.  Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Raymond M. Moore,et al.  Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[38]  D. Littman.  Releasing the Brakes on Cancer Immunotherapy , 2015, Cell.

[39]  W. Bamlet,et al.  Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer , 2015, Cancer Causes & Control.

[40]  W. Bamlet,et al.  Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  C. Denkert,et al.  Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. , 2015, European journal of cancer.

[42]  Bao-sheng Wang,et al.  Long-Term Diabetes Mellitus Is Associated with an Increased Risk of Pancreatic Cancer: A Meta-Analysis , 2015, PloS one.

[43]  B. Vogelstein,et al.  PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Laura H. Tang,et al.  FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma , 2015, Annals of Surgical Oncology.

[45]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Linqiang Zhang,et al.  Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia , 2015, Journal of chemotherapy.

[47]  M. Leitzmann,et al.  Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis , 2015, European Journal of Epidemiology.

[48]  W. Scheithauer,et al.  Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. , 2015, The oncologist.

[49]  Randall W Burt,et al.  ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes , 2015, The American Journal of Gastroenterology.

[50]  F. Roviello,et al.  Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study , 2015, Cancer Chemotherapy and Pharmacology.

[51]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. la Vecchia,et al.  Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis , 2014, British Journal of Cancer.

[53]  Michele L Cote,et al.  BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study , 2014, Genetics in Medicine.

[54]  W. Scheithauer,et al.  nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. , 2015, Journal of the National Cancer Institute.

[55]  J. Taïeb,et al.  Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). , 2014, European journal of cancer.

[56]  J. Kench,et al.  Clinical and pathologic features of familial pancreatic cancer , 2014, Cancer.

[57]  Zheng Wang,et al.  Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. , 2014, Diabetes research and clinical practice.

[58]  H. Ueno,et al.  Improved survival with combined gemcitabine and S‐1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies , 2014, Journal of hepato-biliary-pancreatic sciences.

[59]  J. Windsor,et al.  Factors that affect risk for pancreatic disease in the general population: a systematic review and meta-analysis of prospective cohort studies. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[60]  Peisong Chen,et al.  Prediabetes and the risk of cancer: a meta-analysis , 2014, Diabetologia.

[61]  B. Dörken,et al.  Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Qin Li,et al.  Efficacy and Safety of Gemcitabine-Fluorouracil Combination Therapy in the Management of Advanced Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials , 2014, PloS one.

[63]  R. Gershoni-baruch,et al.  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.

[64]  H. Xian,et al.  Increased risk of pancreatic adenocarcinoma after acute pancreatitis. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[65]  V. Heinemann,et al.  Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody. , 2014, European Journal of Cancer.

[66]  W. Chung,et al.  BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high‐risk pancreatic cancer screening and pancreatic cancer cohorts , 2014, Cancer.

[67]  W. Willett,et al.  Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  W. Baker,et al.  Association Between HBsAg Positivity and Pancreatic Cancer: a Meta-Analysis , 2014, Journal of Gastrointestinal Cancer.

[69]  M. Qi,et al.  Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. , 2014, Genetic testing and molecular biomarkers.

[70]  G. Colditz,et al.  Diabetes and pancreatic cancer survival: a prospective cohort-based study , 2014, British Journal of Cancer.

[71]  B. Hoffman,et al.  Clinical Investigation : Gastrointestinal Cancer Phase 2 Trial of Induction Gemcitabine , Oxaliplatin , and Cetuximab Followed by Selective Capecitabine-Based Chemoradiation in Patients With Borderline Resectable or Unresectable Locally Advanced Pancreatic Cancer , 2022 .

[72]  J. Buscaglia,et al.  Multidisciplinary diagnostic and therapeutic approaches to pancreatic cystic lesions , 2014, Journal of multidisciplinary healthcare.

[73]  A. Ko,et al.  Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[74]  Qing Xu,et al.  Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis , 2014, PloS one.

[75]  F. Weiss.  Pancreatic cancer risk in hereditary pancreatitis , 2014, Front. Physiol..

[76]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[77]  John R. Mackey,et al.  Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. , 2014, Journal of the National Cancer Institute.

[78]  S. Corrao,et al.  Neoadjuvant chemo-radiotherapy for patients with borderline resectable pancreatic cancer: A meta-analytical evaluation of prospective studies , 2012 .

[79]  U. Ballehaninna,et al.  The Impact of Perioperative Blood Glucose Levels on Pancreatic Cancer Prognosis and Surgical Outcomes: An Evidence-Based Review , 2013, Pancreas.

[80]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[81]  A. Hinke,et al.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.

[82]  R. Pietrobon,et al.  Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer: A Trend Analysis Using the Surveillance, Epidemiology, and End Results Registry From 1988 to 2008 , 2013, Pancreas.

[83]  J. Cameron,et al.  Resection of borderline resectable pancreatic cancer after neoadjuvant chemoradiation does not depend on improved radiographic appearance of tumor–vessel relationships , 2013, Journal of Radiation Oncology.

[84]  L. Matrisian,et al.  Pancreatic cancer clinical trials and accrual in the United States. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  R. Hruban,et al.  Management of pancreatic cysts: a multidisciplinary approach , 2013, Current opinion in gastroenterology.

[86]  H. Friess,et al.  European experts consensus statement on cystic tumours of the pancreas. , 2013, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[87]  Fabio Pellegrini,et al.  Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review , 2013, PloS one.

[88]  S. Steinberg,et al.  Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  Edward J. Kim,et al.  A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer , 2013, Cancer.

[90]  A. Krasinskas,et al.  Phase II Study of Induction Fixed-Dose Rate Gemcitabine and Bevacizumab Followed by 30 Gy Radiotherapy as Preoperative Treatment for Potentially Resectable Pancreatic Adenocarcinoma , 2013, Annals of Surgical Oncology.

[91]  M. Pichler,et al.  Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma , 2013, Acta oncologica.

[92]  Suresh T. Chari,et al.  New insights into pancreatic cancer-induced paraneoplastic diabetes , 2013, Nature Reviews Gastroenterology &Hepatology.

[93]  Jeffrey W. Clark,et al.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. , 2013, The oncologist.

[94]  C. F. Fernandez-del Castillo,et al.  Pancreatic cystic neoplasms: management and unanswered questions. , 2013, Gastroenterology.

[95]  D. Goldstein,et al.  Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  M. Murad,et al.  Anti-Diabetic Medications and Risk of Pancreatic Cancer in Patients With Diabetes Mellitus: A Systematic Review and Meta-Analysis , 2013, The American Journal of Gastroenterology.

[97]  J. Berlin,et al.  Borderline Resectable Pancreatic Cancer: Need for Standardization and Methods for Optimal Clinical Trial Design , 2013, Annals of Surgical Oncology.

[98]  P. Tassone,et al.  Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. , 2013, European journal of cancer.

[99]  U. Nöthlings,et al.  Meat and fish consumption and risk of pancreatic cancer: Results from the European Prospective Investigation into Cancer and Nutrition , 2013, International Journal of Cancer.

[100]  A. Hezel,et al.  Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  E. Stepanski,et al.  The Association of Rash Severity With Overall Survival: Findings from Patients Receiving Erlotinib for Pancreatic Cancer in the Community Setting , 2013, Pancreas.

[102]  T. Conroy,et al.  Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  Geoffrey S. Tobias,et al.  Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium , 2013, Cancer Causes & Control.

[104]  E. Kuipers,et al.  Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance , 2012, Journal of Medical Genetics.

[105]  Jeffrey E. Lee,et al.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators , 2012, Cancer.

[106]  M. Saif,et al.  Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer , 2012, Therapeutic advances in medical oncology.

[107]  D. Silverman,et al.  Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[108]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[109]  R. Kelley,et al.  Optimizing the Administration of Fixed-Dose Rate Gemcitabine Plus Capecitabine Using an Alternating-week Schedule: A Dose Finding and Early Efficacy Study in Advanced Pancreatic and Biliary Carcinomas , 2012, American journal of clinical oncology.

[110]  R. Andersson,et al.  Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer? , 2012, World journal of gastroenterology.

[111]  E. Raymond,et al.  FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. , 2012, World journal of gastroenterology.

[112]  Isabelle Salmon,et al.  Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. , 2012, Gastroenterology.

[113]  Marsha A. Ketcham,et al.  Alcohol and Tobacco Lower the Age of Presentation in Sporadic Pancreatic Cancer in a Dose-Dependent Manner: A Multicenter Study , 2012, The American Journal of Gastroenterology.

[114]  J. K. Lee,et al.  New-onset Diabetes Patients Need Pancreatic Cancer Screening? , 2012, Journal of clinical gastroenterology.

[115]  J. Norton,et al.  Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. , 2012, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[116]  A. Miller,et al.  Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[117]  M. Valladares-Ayerbes,et al.  Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[118]  C. la Vecchia,et al.  Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. , 2012, The oncologist.

[119]  G. Abou-Alfa,et al.  Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). , 2012 .

[120]  S. Barni,et al.  FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study , 2012, Cancer Chemotherapy and Pharmacology.

[121]  Jin-Young Jang,et al.  International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. , 2012, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[122]  Ahmedin Jemal,et al.  Annual Report to the Nation on the status of cancer, 1975‐2008, featuring cancers associated with excess weight and lack of sufficient physical activity , 2012, Cancer.

[123]  Y. Ko,et al.  Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO-PK0104) , 2012, Gut.

[124]  S. Jick,et al.  Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis , 2012, The American Journal of Gastroenterology.

[125]  Navid Sadeghi,et al.  Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer , 2012, Clinical Cancer Research.

[126]  Aung Ko Win,et al.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  Jürgen Weitz,et al.  Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer , 2012, Radiation oncology.

[128]  Ahmedin Jemal,et al.  Cancers with increasing incidence trends in the United States: 1999 through 2008 , 2012, CA: a cancer journal for clinicians.

[129]  P Boffetta,et al.  Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[130]  S. Larsson,et al.  Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies , 2012, British Journal of Cancer.

[131]  P. Ruszniewski,et al.  An overview of hereditary pancreatitis. , 2012, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[132]  Yuchen Jiao,et al.  ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.

[133]  J. Manson,et al.  Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[134]  David Cella,et al.  Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[135]  S. Thibodeau,et al.  Pancreatic Cancer and a Novel MSH2 Germline Alteration , 2011, Pancreas.

[136]  M. Robson,et al.  An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. , 2011, The oncologist.

[137]  G. Eslick,et al.  A Systematic Review and Meta-analysis of Survival and Surgical Outcomes Following Neoadjuvant Chemoradiotherapy for Pancreatic Cancer , 2011, Journal of Gastrointestinal Surgery.

[138]  L. Diaz,et al.  A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma , 2011, Cancer Chemotherapy and Pharmacology.

[139]  B. Dörken,et al.  Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. , 2011, European journal of cancer.

[140]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[141]  Matej Horvat,et al.  Microsatellite instability in colorectal cancer , 2011, Radiology and oncology.

[142]  E. Van Cutsem,et al.  Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.

[143]  Laura H. Tang,et al.  Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease , 2011, Annals of Surgical Oncology.

[144]  J. Stockman,et al.  Risk of Pancreatic Cancer in Families With Lynch Syndrome , 2011 .

[145]  G. Weiss,et al.  Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer , 2011, Annals of Surgical Oncology.

[146]  Jeff Myers,et al.  Interconversion of three measures of performance status: an empirical analysis. , 2010, European journal of cancer.

[147]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[148]  H. Friess,et al.  Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. , 2010, JAMA.

[149]  Michael Goggins,et al.  Update on familial pancreatic cancer. , 2010, Advances in surgery.

[150]  R. Schilsky,et al.  Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[151]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[152]  P. Catalano,et al.  Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5‐fluorouracil, and cisplatin followed by radiotherapy and 5‐fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma , 2010, Journal of surgical oncology.

[153]  E. Kuipers,et al.  High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations , 2010, The American Journal of Gastroenterology.

[154]  U. Nöthlings,et al.  Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition , 2010, International journal of cancer.

[155]  R. Labianca,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[157]  A. Lowy,et al.  Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[158]  B. Lau,et al.  Importance of Age of Onset in Pancreatic Cancer Kindreds , 2010, Journal of the National Cancer Institute.

[159]  T. Gauler,et al.  Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ , 2010, Anti-cancer drugs.

[160]  Patrick Maisonneuve,et al.  Epidemiology of pancreatic cancer: an overview , 2009, Nature Reviews Gastroenterology &Hepatology.

[161]  W. Scheithauer,et al.  Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[162]  R. Goldberg,et al.  Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[163]  R. Casadei,et al.  Is type 2 diabetes a risk factor for pancreatic cancer? , 2009, JOP : Journal of the pancreas.

[164]  D. Park,et al.  A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer , 2009, British Journal of Cancer.

[165]  Manal M. Hassan,et al.  Pancreatitis and pancreatic cancer in two large pooled case–control studies , 2009, Cancer Causes & Control.

[166]  M. Thun,et al.  Are Racial Disparities in Pancreatic Cancer Explained by Smoking and Overweight/Obesity? , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[167]  Geoffrey S. Tobias,et al.  Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. , 2009, American journal of epidemiology.

[168]  P. Catalano,et al.  Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  Manal M. Hassan,et al.  Antidiabetic therapies affect risk of pancreatic cancer. , 2009, Gastroenterology.

[170]  D. Silverman,et al.  Dietary fatty acids and pancreatic cancer in the NIH-AARP diet and health study. , 2009, Journal of the National Cancer Institute.

[171]  Jeffrey S. Morris,et al.  Body Mass Index and Risk , Age of Onset , and Survival in Patients With Pancreatic Cancer , 2009 .

[172]  Benjamin D Smith,et al.  Future of cancer incidence in the United States: burdens upon an aging, changing nation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  N. Girard,et al.  Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[174]  W. Scheithauer,et al.  Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[175]  Kenneth J. Chang,et al.  Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement , 2009, Annals of Surgical Oncology.

[176]  Laura H. Tang,et al.  BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  Adam P Dicker,et al.  Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. , 2009, Gastroenterology.

[178]  O. Johannsson,et al.  Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes , 2009, Breast Cancer Research.

[179]  Heather Hampel,et al.  Feasibility of screening for Lynch syndrome among patients with colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  D. Bishop,et al.  Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families , 2008, Clinical Cancer Research.

[181]  K. Hess,et al.  Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second‐line therapy for patients with advanced pancreatic cancer , 2008, Cancer.

[182]  T. Ryan,et al.  Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer , 2008, Annals of Surgical Oncology.

[183]  Steven Gallinger,et al.  Germline BRCA1 mutations predispose to pancreatic adenocarcinoma , 2008, Human Genetics.

[184]  M. Saif.  New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008. , 2008, JOP : Journal of the pancreas.

[185]  A. Benson,et al.  A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 , 2008 .

[186]  B. Dörken,et al.  A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study , 2008 .

[187]  R. Abrams,et al.  Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. , 2008, JAMA.

[188]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[189]  R. Labianca,et al.  Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[190]  Manal M. Hassan,et al.  Risk Factors for Pancreatic Cancer: Case-Control Study , 2007, The American Journal of Gastroenterology.

[191]  Douglas B. Evans,et al.  Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy , 2007, Cancer.

[192]  W. Scheithauer,et al.  Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[193]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[194]  S. Larsson,et al.  Body mass index and pancreatic cancer risk: A meta‐analysis of prospective studies , 2007, International journal of cancer.

[195]  Giovanni Parmigiani,et al.  PancPRO: risk assessment for individuals with a family history of pancreatic cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[196]  E. Touboul,et al.  Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[197]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[198]  K. Brown,et al.  Neoadjuvant Therapy in Pancreatic Cancer , 2007, Cancer investigation.

[199]  V. Valentini,et al.  Preoperative Chemoradiation and Intra-Operative Radiotherapy for Pancreatic Carcinoma , 2007, Tumori.

[200]  C. Mcginn,et al.  Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas , 2003, Journal of Gastrointestinal Surgery.

[201]  M. Desai,et al.  The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis , 2007, Cancer Chemotherapy and Pharmacology.

[202]  E. Vittinghoff,et al.  New-onset diabetes and pancreatic cancer. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[203]  A. Muratore,et al.  Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival , 2006, Annals of Surgical Oncology.

[204]  H. Einsele,et al.  Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[205]  K. Syrigos,et al.  A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer , 2006, British Journal of Cancer.

[206]  Jeffrey E. Lee,et al.  Borderline Resectable Pancreatic Cancer: Definitions, Management, and Role of Preoperative Therapy , 2006, Annals of Surgical Oncology.

[207]  F. Gay,et al.  Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study , 2006, British Journal of Cancer.

[208]  N. Girard,et al.  Radiochemotherapy in the management of pancreatic cancer--part I: neoadjuvant treatment. , 2005, Seminars in radiation oncology.

[209]  P. Devilee,et al.  Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma , 2005, Cancer.

[210]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[211]  Mariza de Andrade,et al.  Probability of pancreatic cancer following diabetes: a population-based study. , 2005, Gastroenterology.

[212]  M. Reni,et al.  Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. , 2005, The Lancet. Oncology.

[213]  R. Labianca,et al.  Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[214]  W. Frankel,et al.  Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). , 2005, The New England journal of medicine.

[215]  T. Conroy,et al.  Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  Il-Jin Kim,et al.  [Hereditary colorectal cancer]. , 2005, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[217]  M. Thun,et al.  Obesity, Recreational Physical Activity, and Risk of Pancreatic Cancer In a Large U.S. Cohort , 2005, Cancer Epidemiology Biomarkers & Prevention.

[218]  F. Couch,et al.  Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. , 2005, Cancer research.

[219]  W. Miller,et al.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[220]  Alison P. Klein,et al.  Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.

[221]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[222]  W. Greenhalf,et al.  Clinical and genetic characteristics of hereditary pancreatitis in Europe. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[223]  B. Karlan,et al.  Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[224]  J. Abbruzzese,et al.  Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine , 2004, Cancer Chemotherapy and Pharmacology.

[225]  J. Hainsworth,et al.  Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  R. Hruban,et al.  Fanconi anemia gene mutations in young-onset pancreatic cancer. , 2003, Cancer research.

[227]  T. Conroy,et al.  An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[228]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[229]  J. Tepper,et al.  Cancer and leukemia group B (CALGB) 89805 , 2003 .

[230]  P. Ruszniewski,et al.  Risk of pancreatic adenocarcinoma in chronic pancreatitis , 2002, Gut.

[231]  Daniel G Haller,et al.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[232]  T. Hickish,et al.  Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[233]  G. Colucci,et al.  Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma , 2002, Cancer.

[234]  T. Szatrowski,et al.  Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[235]  S. Kern,et al.  Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma–pancreatic carcinoma–prone families , 2002, Cancer.

[236]  E. Paulson,et al.  Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas , 2001, Annals of Surgical Oncology.

[237]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[238]  W. Bautz,et al.  Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study , 2000, Oncology Research and Treatment.

[239]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[240]  R. Hruban,et al.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. , 1999, The American journal of pathology.

[241]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[242]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[243]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[244]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[245]  J. Nezu,et al.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. , 1998, Nature genetics.

[246]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[247]  L. Traverso,et al.  Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). , 1997, American journal of clinical oncology.

[248]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[249]  M. Tamburini,et al.  Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. , 1996, European journal of cancer.

[250]  R H Hruban,et al.  Familial pancreatic cancer: a review. , 1996, Seminars in oncology.

[251]  P. Goodfellow,et al.  Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. , 1995, The New England journal of medicine.

[252]  J K McLaughlin,et al.  Pancreatitis and the risk of pancreatic cancer. , 1993, The New England journal of medicine.

[253]  N. Abourizk,et al.  New‐Onset Diabetes Mellitus as a Harbinger of Pancreatic Carcinoma A Case Report and Literature Review , 1989, Journal of clinical gastroenterology.

[254]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[255]  P. Engstrom,et al.  Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[256]  T. F. Mancuso,et al.  Cohort study of workers exposed to betanaphthylamine and benzidine. , 1967, Journal of occupational medicine. : official publication of the Industrial Medical Association.